GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Pubmed ID: 32556329
Publication Date: //

Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation.


We investigated a patient with systemic juvenile idiopathic arthritis (sJIA) and recurrent macrophage activation syndrome (MAS) to discover genetic and immunological contributing factors.

Severe recurrent MAS motivated whole exome sequencing (WES) to identify genetic variants potentially involved in disease pathogenesis. In vitro peripheral blood mononuclear cell (PBMC) stimulations for cytokine expression and caspase-1 activity assays as well as NF-κB reporter luciferase assays were performed to functionally characterize variants.

WES revealed an extremely rare heterozygous missense variant, c.482G>A, p.R161H in the CASP1 gene encoding pro-caspase-1. Lipopolysaccharide (LPS) stimulation of patient PBMCs induced high levels of IL-6 compared to controls, and activation of the NLRP3 inflammasome resulted in increased production of IL-1β and IL-18 as well as significantly elevated caspase-1 activity. Constitutive and inducible levels of IL-18 and IFNγ in whole blood were markedly elevated. Expression of the CASP1 variant in an NF-κB reporter luciferase assay induced increased NF-κB activation in a RIP2-dependent manner. The disease course of the patient was complicated by severe recurrent MAS. However, dual IL-1 and IL-6 blockade caused disease remission.

For the first time, we demonstrate the involvement of a CASP1 variant in sJIA and recurrent MAS. This variant is gain-of-function for both inflammasome and NF-κB activation leading to increased production of IL-6, IL-1β and IL-18. Although dual IL-1 and IL-6 blockade may be beneficial in patients, in whom single treatment is not sufficient to control MAS, caution should be practiced, since interstitial lung disease may progress despite apparent clinical and biochemical remission.
Authors: Jørgensen Sofie E , Christiansen Mette , Høst Christian , Glerup Mia , Mahler Birgitte , Lausten Mira M , Gad Hans Henrik , Hartmann Rune , Herlin Troels , Mogensen Trine H ,

Reference:

  1. ncbi.nlm.nih.gov. [Last access //].

Related products :

Catalog number Product name Quantity
18-003-42916 Small inducible cytokine A18 - CCL18; Macrophage inflammatory protein 4; MIP-4; Pulmonary and activation-regulated chemokine; CC chemokine PARC; Alternative macrophage activation-associated CC chemoki 0.05 mg Aff Pur
10-663-45029 Macrophage Inflammatory Protein-4 (MIP-4) Human - CCL18; Macrophage inflammatory protein 4; MIP-4; Pulmonary and activation-regulated chemokine; CC chemokine PARC; Alternative macrophage activation-as 0.01 mg
10-663-45029 Macrophage Inflammatory Protein-4 (MIP-4) Human - CCL18; Macrophage inflammatory protein 4; MIP-4; Pulmonary and activation-regulated chemokine; CC chemokine PARC; Alternative macrophage activation-as 0.002 mg
10-663-45029 Macrophage Inflammatory Protein-4 (MIP-4) Human - CCL18; Macrophage inflammatory protein 4; MIP-4; Pulmonary and activation-regulated chemokine; CC chemokine PARC; Alternative macrophage activation-as 1 mg
10-288-22230F Wolf-Hirschhorn syndrome candidate 2 protein variant - 0.05 mg